Dr. Michel E. Kuzur: Mesothelioma Doctor at Tennessee Oncology

Quick Facts

Primary Location:
Tennessee Oncology
Expertise:
Chemotherapy
Bone Marrow Biopsies
Speciality:
Hematology
Gender:
Male
Language:
English
Med School:
American University

Get to Know Dr. Michel E. Kuzur

Medical oncologist Dr. Michel E. Kuzur has been caring for cancer patients for four decades, combining his vast experience with the latest clinical research to provide first-rate, personalized treatment for his patients.

Since 1994, Kuzur has been with Tennessee Oncology, one of the country’s largest community based cancer-care groups. The group has a growing network of top-level physicians.

Kuzur sees patients at the TriStar Skyline Medical Center and the TriStar Centennial Medical Center in Nashville. He treats many different adult malignancies, including lung cancer, mesothelioma, kidney cancer, prostate cancer and Hodgkin’s lymphoma.

He has been practicing medicine since 1981 and has played a key role in Tennessee Oncology’s reputation for high-quality care and expertise in clinical research.

Contact Dr. Michel Kuzur

615-860-1556

Specialties of Dr. Michel E. Kuzur

Medical oncology
Hematology
Lung cancer
Chemotherapy
Bone marrow biopsies

Dr. Michel E. Kuzur’s Experience and Medical Education

Tennessee Oncology
Miller Medical Group
University of Massachusetts Memorial Hospital (Residency)
Vanderbilt University Medical Center (Fellowship)
American University of Beirut (Internship and M.D.)

Awards and Other Recognitions

Patients’ Choice Award
Nashville Academy of Medicine (Member)
American Society of Clinical Oncology (Member)
American Society of Hematology (Member)

See More Top Mesothelioma Doctors

Publications of Dr. Michel E. Kuzur

Bendell, J. et al. (2017, April). A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer Investigation.
Kuzur, M. et al. (2005, June). Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology.